In WHO grade 2 and 3 gliomas, detection of mutations in the tumor protein 53 (Tp53) gene or ATRX loss suffice for astrocytoma diagnosis, making 1p19q codeletion analysis non-obligatory in these cases (Louis et al., 2018, 2021). Here, TP53 is linked to glioma.